

## HalioDx part of the COLOSSUS project to improve treatment for colorectal cancer patients

- COLOSSUS aim is to better stratify metastatic colorectal patients for improving treatments
- The project gathers a large European consortium of leading cancer centers and private companies
- HalioDx is exploring immuno-oncology mechanisms to contribute to the identification of new treatment strategies in this difficult-to-treat patient population

Marseille, France, March 29, 2018 – HalioDx SAS, an immuno-oncology diagnostic company, announced its participation in the COLOSSUS project, led by the RCSI (Royal College of Surgeons in Ireland), conducted in close collaboration with prestigious clinical research centers in Europe and supported by the European Commission's Horizon 2020 program. The project will run for 5 years and formally started in January 2018.

COLOSSUS is funded by an EU-Horizon 2020 grant, named “New concepts in patient stratification” and was ranked #1 out of 206 applications submitted to H2020 Personalized Medicine Call from across Europe in 2017.

The COLOSSUS project (€ 6 millions) aim is to provide new and more effective stratification tools and therapeutic interventions, specifically tailored to a genetically defined form of metastatic (m) colorectal cancer (CRC) called microsatellite stable (MSS) RAS mutant (mt) disease which is incurable once patients develop resistance to existing therapies. The project gathers a large European consortium of leading cancer centers from Ireland, Spain, UK, Belgium, Germany, and Italy. The project is led by Professor Annette Byrne, Associate Professor, RCSI Dept of Physiology and Medical Physics and RCSI Centre for Systems Medicine and the scientific Programme is jointly directed by Dr Rodrigo Dienstmann (VHIO, Barcelona, Spain) and Prof Jochen Prehn (RCSI, Dublin, Ireland).

The project will focus on the critical requirement for in-depth biological interrogation and refinement of CRC subtypes, in particular to deliver new models for MSS RAS mt patient stratification and treatment that take into consideration not only genomics and transcriptomics but also epigenomics, proteomics, metabolic and immunological features.

Immunoscore® Colon and newly described MSS RAS mt classifiers will be validated as novel patient stratification tools within the COLOSSUS trial, a multicentre clinical study for advanced MSS RAS mt mCRC patients which will be conducted across Spain, Germany and Ireland.

### **Vincent FERT, CEO of HalioDx comments:**

*“HalioDx is very excited to be part of the COLOSSUS consortium to drive medical innovation for patient’s care. This project is uniquely positioned to perform novel and integrated pathway analyses and to deliver and robustly test novel MSS RAS mt classifiers and new combinatorial therapeutic strategies. Working with the project leading experts in colorectal cancer, we are committed to demonstrate that our biomarker technology is broadly applicable in Immuno-oncology diagnostics.”*

For more information about COLOSSUS project, visit <https://www.colossusproject.eu/> and follow @COLOSSUSEU

## About HalioDx

### The Immune Response to Cancer Diagnostics

HalioDx is an immuno-oncology diagnostic company providing oncologists with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.

Immunoscore® proprietary technology, Pioneered by Jérôme Galon at the Cordeliers Research Center, Paris, France, integrates immunohistochemistry combined with sophisticated algorithm and advanced imaging analysis enabling extraction of spatially-organized tissue molecular information. Immunoscore® is a platform for many cancers, as immune response to tumor is a key hallmark of disease progression. HalioDx collaborates with renowned international clinical groups to support clinical utility and ensure rigorous performance validation of its assays in selected cancer indications.

Two additional assays, Halioseek & Immunosign have been developed by HalioDx and provide tools to help stratifying patients for immunotherapies.

HalioDx has an experienced team of more than 130 employees, a CLIA-certified laboratory and compliant facilities to develop, manufacture, register and market *in vitro* diagnostic (IVD) products. HalioDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies. The company co-founded the European immunology cluster Marseille Immunopôle (MI).

For more information, please visit our websites [www.halioldx.com](http://www.halioldx.com) and [www.immunoscore-colon.com](http://www.immunoscore-colon.com) and follow the company on Twitter [@HalioDx](https://twitter.com/HalioDx).

## Contacts

### HalioDx SAS

#### Vincent Fert

President and CEO

+ 33 (0)4 91 29 30 90

[vincent.fert@halioldx.com](mailto:vincent.fert@halioldx.com)

### ATCG Press

Marie Puvieux (France)

Mob: +33 (0)6 10 54 36 72

Céline Voisin (ROW)

Mob: +33 (0)6 62 12 53 39

[halioldx@atcg-partners.com](mailto:halioldx@atcg-partners.com)